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REBUTTING OBVIOUSNESS IN THE PHARMACEUTICAL
INDUSTRY: SECONDARY CONSIDERATIONS OF ANALOGS
Jolie D. Lechner*
Abstract
Pharmaceutical companies depend on patent protection to recuperate the high costs of
research and development. In regards to the patentability of structurally related
compounds, the courts must decide whether a compound is obvious in view of its
structurally similar prior art. In general, a compound is non-obvious over the structurally
related prior art if the compound exhibits unexpected results. However, placing primary
emphasis on a compound’s unexpected properties is out of step with the realities of drug
development. For example, during drug development, chemists will modify a
compound’s structure until they produce a compound that exhibits optimal pharmakinetic
properties. This iterative process relies on the perseverance of scientists to pave the road
to drug discovery—not unexpected results.
This Note advocates for the elevation of the failure of others to make a drug that benefits
society and the long-felt but unmet need for that treatment in the obviousness inquiry.
These factors highlight the underappreciated realities of the drug discovery process, the
immense effort that precedes a drug’s delivery to market, and the profound effect
pharmaceuticals can have on disease treatment. In giving greater credence to the failure
of others to develop a drug and the unmet need for that treatment, courts can resolve the
current disconnect between the laboratory and patent law. By rewarding innovators that
embark on a logical research plan that ends in the development of a beneficial drug,
patent law will encourage companies to invest in drug development and produce drugs
that benefit society.
INTRODUCTION
“[P]atents are not barred just because it was obvious ‘to explore a new technology
or general approach that seemed to be a promising field of experimentation.’”1 This was
illustrated early on in The Incandescent Lamp Patent case.2 In that case, the Supreme
Court invalidated a patent for an incandescent lamp that used a conductor composed of
“fibrous or textile material.”3 While the Court reasoned that the specification was “too
*

J.D. Candidate, 2012, Case Western Reserve University School of Law; Ph.D., 2009, University of
Pittsburgh; B.S., 2003, The Pennsylvania State University. The author would like to thank Professors
Jacqueline Lipton and Raymond Ku for their helpful comments and Matthew Lechner for his never-ending
support.
1
Procter & Gamble Co. v. Teva Pharm. USA, Inc., 566 F.3d 989, 997 (Fed. Cir. 2009) (quoting In re
O’Farrell, 853 F.2d 894, 903 (Fed. Cir. 1988)).
2
The Incandescent Lamp Patent, 159 U.S. 465 (1895).
3
Id. at 471.
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indefinite . . . [for a] valid monopoly,” the Court’s decision was grounded in economics.4
Simply put, the plaintiffs’ lamp “was never a commercial success” due to the “defective”
lamp chamber.5 It was Thomas Edison, the alleged infringer, who produced a domestic
lamp fit for the marketplace. While Edison’s design certainly had precedents in earlier,
ineffective incandescent lamp designs, his ceaseless efforts to perfect the device resulted
in a working product. Only after extensive experimentation with conductor thickness,
“thirty or forty different woods of exogenous growth,” and various types of bamboo from
China and Japan did Edison develop a useful light bulb.6 This invention met society’s
long-felt but unmet need for artificial light at night. As a result, the Court refused to allow
the plaintiffs’ “imperfectly successful experiments” to stand in the way of Edison’s
“brilliant discover[y].”7
The issues underlying the Supreme Court’s decision are still relevant in patent law
today. While the statutory definition of non-obviousness8 did not exist at the time of The
Incandescent Lamp Patent, the Court placed emphasis on factors like the failure of the
other inventors to create a working lamp and the public’s long-felt need for artificial
light.9 Today, courts look to these factors, called secondary considerations, as evidence of
non-obviousness, which is a requirement for patentability.10
In the pharmaceutical industry, evaluating the non-obviousness of new chemical
compounds requires a nuanced analysis.11 Drug development is “profoundly affected” by
structurally related compounds like enantiomers, isomers, and analogs. 12 Thus, the
statutory hurdle of non-obviousness 13 plays an increasingly important role in the
patentability of such compounds. The Federal Circuit has maintained that “structural
similarity between claimed and prior art subject matter, proved by combining references
4

Id. at 477.
Id. at 471.
6
Id. at 473-74.
7
Id. at 474.
8
In 1952 Congress codified the non-obviousness requirement of patentability in 35 U.S.C. §103; for
commentary regarding the enactment of 35 U.S.C. §103 see CRAIG A. NARD, THE LAW OF PATENTS 321-26
(2008).
9
The Incandescent Lamp Patent, 159 U.S. at 471-77.
10
Graham v. John Deere Co., 383 U.S. 1, 17-18 (1966); KSR Int’l Co. v. Teleflex Inc., 550 U.S. 398, 406
(2007) (reaffirming Graham v. John Deere Co.).
11
While structurally similar compounds can appear deceptively obvious, making small changes in a
compound’s structure can result in molecules with vastly different biological and pharmacological
properties. As a result, structurally related compounds have presented the courts with a complex
obviousness analysis that has evolved into a distinct area of patent law. See Rebecca M. Wilson & Samuel
J. Danishefsky, Small Molecule Natural Products in the Discovery of Therapeutic Agents: The Synthesis
Connection, 71 J. ORG. CHEM. 8329, 8336 (2006) (“Even with all of the advances, ours is a fickle science
of limited predictive capacity. The fact that so much success has been accomplished should not obscure the
fact that there is so much that we do not know how to do at all, or can do only poorly.”); In re Jones, 958
F.2d 347, 349 (Fed. Cir. 1992) (noting that “[t]he question of ‘structural similarity’ in chemical patent cases
has generated a body of patent law unto itself”).
12
For a minireview regarding the challenge presented by the structurally related compounds atropisomers
see Jonathan Clayden et al., The Challenge of Atropisomerism in Drug Discovery, 48 ANGEW. CHEM. INT.
ED. 6398, 6398 (2009).
13
35 U.S.C. §103.
5
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or otherwise, where the prior art gives reason or motivation to make the claimed
compositions, creates a prima facie case of obviousness.” 14 In other words, a lead
compound’s structure can provide motivation for further structural modifications
resulting in new, but obvious compounds.15 For example, the Federal Circuit in In re
Dillon considered the obviousness of tetra-orthoesters with respect to tri-orthoesters in
the area of fuel chemistry.16 While both classes of compounds function as fuel additives,
tetra-orthoesters reduce the emission of solid particulates during combustion whereas triorthoesters prevent phase separation between fuel and alcohol co-solvents.17 Despite this
difference, due to the structural similarity between tetra- and tri-orthoesters and their
similar applications as fuel additives, the Federal Circuit reaffirmed that the applicant’s
tetra-orthoesters were prima facie obvious. 18 Furthermore, the court noted that the
applicant “had the opportunity to rebut the prima facie case,” but failed to demonstrate
that the tetra-orthoesters possessed “unexpectedly improved properties” over the prior
art.19
As illustrated by In re Dillon, courts have tuned the obviousness analysis in
chemical patent cases to center on unpredictable results. Thus, a patentee can rebut the
prima facie case of obviousness based on structural similarity if the claimed compound
“possess[es] unexpectedly improved properties” over the prior art.20 To date, case law has
“recogniz[ed] the vital role” of unexpected results in defeating obviousness allegations in
the context of structural similarity.21 For example, consider the obviousness of Type 2
diabetes drug pioglitazone, which belongs to a known class of compounds called
thiazolidinediones (“TZDs”).22 While pioglitazone has a close structural relationship to a
prior art compound with antidiabetic activity, the Federal Circuit held that the
compound’s “unexpectedly superior properties” rendered the molecule non-obvious.23
Likewise, in Proctor & Gamble Co. v. Teva Pharmaceuticals, the Federal Circuit
reaffirmed that risedronate, the active ingredient of P&G’s osteoporosis drug Actonel®,
14

Takeda Chem. Indus. v. Alphapharm. Pty., Ltd., 492 F.3d 1350, 1356 (Fed. Cir. 2007) (quoting In re
Dillon, 919 F.2d 688, 692 (Fed. Cir. 1990)); see also Sanofi-Synthelabo v. Apotex, Inc., 550 F.3d 1075,
1086 (Fed. Cir. 2008) (“Precedent establishes the analytical procedure whereby a close structural similarity
between a new chemical compound and prior art compounds is generally deemed to create a prima facie
case of obviousness.”); In re Payne, 606 F.2d 303, 314-15 (C.C.P.A. 1979) (noting “the presumption of
obviousness based on close structural similarity”); see generally Helmuth A. Wegner, Prima Facie
Obviousness of Chemical Compounds, 6 APLA Q. J. 271 (1978) (discussing prima facie obviousness of
structurally related compounds such as homologs, isomers, stereoisomers, etc.).
15
Takeda Chem. Indus., Ltd., 492 F.3d at 1356 (quoting In re Deuel, 51 F.3d 1552, 1558 (Fed. Cir. 1995)).
16
In re Dillon, 919 F.2d 688, 690-91 (Fed. Cir. 1990) (en banc).
17
Id. at 690.
18
Id. at 692.
19
Id. at 692-93.
20
Id. at 692-93.
21
Takeda Chem. Indus., 492 F.3d 1350, 1364 (Dyk, J., concurring); see also Pfizer, Inc. v. Apotex, Inc.,
480 F.3d 1348, 1371 (Fed. Cir. 2007) (finding a species claim obvious because Pfizer “simply failed to
prove that the results [were] unexpected”); Altana Pharma AG v. Teva Pharm. USA, Inc., 566 F.3d 999,
1010 (Fed. Cir. 2009) (reaffirming the district court’s finding that “the purportedly unexpected property of
pantoprazole is in fact an expected property . . . . [showing] a sufficient case of obviousness to defer the
matter for trial on the merits”).
22
Takeda Chem. Indus., 492 F.3d at 1352-53.
23
Id. at 1361-62.
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was non-obvious due to unexpected properties.24 In reaching its decision, the Federal
Circuit placed emphasis on a researcher’s testimony that she was “very surprised” at
risedronate’s efficacy and a doctor’s statement that “the superior properties of risedronate
were unexpected and could not have been predicted.”25
The reasoning underlying the relationship between patentability and unpredictable
results is understandable: how could an invention be obvious if its properties catch the
inventor off-guard? But this test is often at odds with the reality of how drug
development is performed.26 For example, in small molecule R & D, chemists will make
minor modifications to a lead compound’s structure with the goal of optimizing its
efficacy and safety.27 The compounds that show promising activity are subjected to
animal studies as well as human testing during three consecutive phases of clinical
trials.28 During this long and expensive process, many compounds are abandoned along
the way due to insufficient efficacy and safety concerns. 29 All the while, chemists
continue to modify the lead structure until optimal pharmakinetic properties are
achieved.30 This methodical process relies on the perseverance of scientists to pave the
road to drug discovery—not on unpredictable results.31
The disconnect between laboratory methods and the courtroom’s standards for
obviousness threatens to stifle the development of innovative drugs. Pharmaceutical
science is a risky business that relies on patent protection to fuel costly research and
development.32 For example, developing a new drug fit for the marketplace can take
24

Procter & Gamble Co. v. Teva Pharm. USA, Inc., 566 F.3d 989, 997.
Id.
26
See Kristen C. Buteau, Deuterated Drugs: Unexpectedly Nonobvious?, 10 J. HIGH TECH. L. 22, 23 (2009)
(commenting that “pharmaceutical patents are especially susceptible to an obviousness challenge because
the natural progression of science necessarily builds upon past discoveries and requires considerable
experimentation through trial and error, thereby potentially rendering the invention obvious-to-try”).
27
See generally RICHARD B. SILVERMAN, THE ORGANIC CHEMISTRY OF DRUG DESIGN AND DRUG ACTION,
17-61 (2d ed. 2004).
28
For a description of clinical trials during drug development see Joseph A. DiMasi et al., The Price of
Innovation: New Estimates of Drug Development Costs, 22 JOURNAL OF HEALTH ECONOMICS 151, 155-56
(2003).
29
YALI FRIEDMAN, BUILDING BIOTECHNOLOGY: BUSINESS, REGULATIONS, PATENTS, LAW, POLITICS,
SCIENCE 45-46 (3d ed. 2008) (commenting that “[t]he Tufts Center for the Study of Drug Development
found that only five in five thousand small-molecule compounds that enter pre-clinical testing make it to
human testing. Of these five, only one is approved”).
30
SILVERMAN, supra note 27, at 17-18; Expert Report of John G. Gleason, Ph.D. on Patent Validity at 4,
Merck Sharp & Dohme Pharm., SRL v. Teva Pharm. USA, Inc., No. 07-1596 (GEB)(JJH), 2009 WL
3153316 (D.N.J. Aug. 19, 2009).
31
SILVERMAN, supra note 27, at 17 (noting that, “rational approaches [in drug development] are directed at
lead discovery. It is not possible, with much accuracy, to foretell toxicity and side effects, anticipate
transport characteristic, or predict the metabolic fate of a drug. Once a lead is identified, its structure can be
modified until an effective drug is prepared”).
32
Michael Enzo Furrow, Analyzing the Laws, Regulations, and Policies Affecting FDA-Regulated
Products: Pharmaceutical Patent Life-Cycle Management After KSR v. Teleflex, 63 FOOD & DRUG L.J.
275, 278 (2008); see also Biotechnology Indus. Org. v. District of Columbia, 496 F.3d 1362, 1372 (Fed.
Cir. 2007) (“We have long acknowledged the importance of the patent system in encouraging innovation.
Indeed, ‘the encouragement of investment-based risk is the fundamental purpose of the patent grant, and is
based directly on the right to exclude.’ . . . Importantly, the patent system provides incentive to the
25
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innovator drug firms ten to fifteen years33 and cost $1.5 billion per drug.34 With little
more than the hope of unpredictable results to rely on in obtaining much-needed patent
rights, pharmaceutical companies will not invest in the lengthy and uncertain process of
drug discovery.35 Considering that “pharmaceutical products increase longevity, improve
the quality of life, and often result in medical cost savings,”36 courts should rely on
objective indicia of non-obviousness that do not “penalize[] people in areas of endeavor
where advances are won only by great effort and expense.”37
Giving greater credence to additional considerations, such as the failure of others
to develop a drug that fulfills society’s long-felt need for disease treatment, will
encourage companies to develop drugs that benefit society.38 Unlike the unpredictable
results analysis, these factors (1) reward innovators that have the skill to execute a bright
idea; and (2) encourage companies to pursue difficult projects whose completion can
greatly benefit society. In other words, a company could give their support to a
“researcher [who] dared to follow a logical plan”39 with some confidence that their
support would be rewarded.
The introduction of this Note introduces the real-world significance of others’
failures to meet a long-felt but unmet societal need in advancing technology. Part I
provides background into the patent system and the obviousness of structurally related
compounds. Part II uses two recent pharmaceutical patent cases, Eli Lilly & Co. v. Sicor
Pharmaceuticals, Inc. 40 and Merck Sharp & Dohme Pharmaceuticals, SRL v. Teva
Pharmaceuticals USA, Inc.,41 to illustrate the paramount role of (1) others’ unsuccessful
efforts; and (2) the societal benefits of the drugs that meet a long-felt need in establishing
non-obviousness. Part III proposes that courts should place primary emphasis on the
failure of others and long-felt need in the obviousness analysis of structurally related
innovative drug companies to continue costly development efforts.”) (quoting Sanofi-Synthelabo v.
Apotex, Inc., 470 F.3d 1368, 1383 (Fed. Cir. 2006)).
33
Furrow, supra note 32, at 278.
34
Id. at 283.
35
See Carmelo Giaccotto et al., Drug Prices and Research and Development Investment Behavior in the
Pharmaceutical Industry, 48 J. LAW & ECON. 195, 211 (2005) (commenting that scholars have argued that
“the most innovative drugs are riskier and costlier to produce but presumably have the greatest social
benefits”).
36
Id. at 195.
37
In re Merck & Co., 800 F.2d 1091, 1100 (Baldwin, J., dissenting) (arguing that the obvious-to-try test
should not be applied to research areas that are high cost and labor-intensive, e.g., pharmaceuticals).
38
See Joseph P. Meara, Note, Just Who is the Person Having Ordinary Skill in the Art? Patent Law’s
Mysterious Personage, 77 WASH. L. REV. 267, 295-96 (2002) (“Long-felt need and failure of others to
make the invention should not be utilized as ‘secondary’ considerations, but rather as objective evidence of
actual skill in the art . . . When a problem is old in the art and has been the subject of more than de minimus
research, it suggests that no one of any skill level was able to solve it. When combined with actual evidence
that others failed to solve the problem, one can infer that the solution has eluded those of ordinary skill.”).
39
In re Merck & Co., 800 F.2d at 1100 (Baldwin, J., dissenting) (arguing that the obvious-to-try analysis is
inapplicable to the pharmaceutical field because the test would render any effective drug obvious simply
because it followed from “a logical research plan”).
40
Eli Lilly & Co. v. Sicor Pharm., Inc., 705 F. Supp. 2d 971 (S.D. Ind. 2010).
41
Merck Sharp & Dohme Pharm., SRL v. Teva Pharm. USA, Inc., No. 07-1596 (GEB)(DEA), 2009 WL
3153316 (D.N.J. Aug. 19, 2009).
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compounds like analogs. Finally, this Article concludes that the patent system’s
recognition of others’ unsuccessful efforts to satisfy a long-felt need is necessary to
encourage drug development.
I. BACKGROUND: REQUIREMENTS FOR PATENTABILITY
A. The Patent System
Patent law is grounded in incentives.42 The United States Patent and Trademark
Office (“PTO”) induces inventors to disclose their discovery to the public by offering a
financial reward.43 To obtain a patent, the inventor must disclose subject matter that is
novel,44 useful,45 and non-obvious.46 Patent law’s novelty requirement bars a patent for
an invention that is not new.47 For example, an invention is not novel if “it was made
before; it was sold more than a year before a patent application was filed; or it was
otherwise subject to prior use or knowledge.”48 In addition to being novel, patent-worthy
inventions must be useful.49 This requirement is easily met, as an invention need only
work under experimental conditions.50
The “final gatekeeper of the patent system” is the non-obviousness requirement.51
Obviousness is regarded as the “ultimate condition of patentability”52 because it evaluates
the technical merits of an invention.53 This statutory prerequisite considers “whether an
invention is a big enough technical advance” to warrant patent protection.54 While nonobviousness is “the most important requirement”55 for patentability, it has catalyzed
“controversy”56 regarding the patentability of structurally similar compounds.57
42

Giles S. Rich, The Vague Concept of “Invention” as Replaced by § 103 of the 1952 Patent Act, 14 FED.
CIR. B.J. 147 (2004); but see David Conforto, Traditional and Modern-Day Biopiracy: Redefining the
Biopiracy Debate, 19 J. ENVTL. L. & LITIG. 358, 367-68 (2004) (arguing that patent law disincentives
scientific breakthroughs because patent rights are awarded to a “MegaPharm” company rather than the
“innovator who actually makes the discovery”); Robert P. Merges, Uncertainty and the Standard of
Patentability, 7 HIGH TECH. L.J. 1, 5 (1992) (noting that “it is safe to say there is a consensus among
economists that in the aggregate patents offer only a very limited incentive to invent”).
43
NARD, supra note 8, at 2.
44
35 U.S.C. § 102.
45
35 U.S.C. § 101.
46
35 U.S.C. § 103.
47
35 U.S.C. § 102; see also NARD, supra note 8, at 187-88.
48
Robert P. Merges, Commercial Success and Patent Standards: Economic Perspectives on Innovation, 76
CAL. L. REV. 803, 811 (1988).
49
35 U.S.C. § 101.
50
Merges, supra note 48, at 812.
51
Id.
52
NONOBVIOUSNESS: THE ULTIMATE CONDITION OF PATENTABILITY (John F. Witherspoon ed., 1980).
53
Merges, supra note 48, at 812.
54
Id.
55
Id.
56
See Donald R. Dunner & Ronald P. Kananen, Nonobviousness and the Court of Customs and Patent
Appeals—Twenty-Five Years in Review, in NONOBVIOUSNESS, supra note 52, at 3:114 (commenting “that
Section 103 is, despite its seeming clarity, a generator of controversy”).
57
In re Jones, 958 F.2d 347, 349 (Fed. Cir. 1992) (“The question of ‘structural similarity’ in chemical
patent cases has generated a body of patent law unto itself.”) (citing Helmuth A. Wegner, supra note 14).
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B. Determining Obviousness
In Graham v. John Deere Co., the Supreme Court outlined the test for
determining obviousness.58 The Court determined that “[u]nder [35 U.S.C.] § 103, the
scope and content of the prior art are to be determined; differences between the prior art
and the claims at issue are to be ascertained; and the level of ordinary skill in the
pertinent art resolved.” 59 Notably, the Supreme Court authorized courts to also use
secondary considerations such as commercial success, the failure of others, long-felt but
unmet needs,60 and unexpected results in evaluating obviousness.61
Secondary considerations, 62 also called objective considerations, consider
“evidence outside the intrinsic features of the invention and focus on the real-world
circumstances surrounding [an invention’s] origin and commercialization.”63 When there
is a nexus between such considerations and the merits of the claimed invention, 64
secondary considerations “alone may defeat a claim of obviousness.”65 Moreover, such
objective considerations “may often be the most probative and cogent evidence in the
record.”66 Thus, secondary considerations are not just “icing on the cake,”67 but “must be
considered before the conclusion on obviousness is reached.”68 For example, in Eli Lilly
& Co. v. Zenith Goldline Pharmaceuticals,69 the District Court for the Southern District
of Indiana opined that even though the defendants “failed to establish a prima facie case
of structural obviousness [of the drug olanzapine] . . . . the court is required to examine
the objective evidence of nonobviousness in the record.”70 Thus, only after the court
evaluated: (1) the long-felt need for a better antipsychotic drug like olanzapine; (2) the
failure of others to develop a safe antipsychotic drug; (3) olanzapine’s commercial

58

Graham v. John Deere Co., 383 U.S. 1, 17; KSR Int’l Co. v. Teleflex Inc. 550 U.S. 398, 406 (reaffirming
Graham v. John Deere Co.).
59
Graham v. John Deere Co., 383 U.S. at 17.
60
Id. at 17-18; see Merges, supra note 48, at 816-19 for commentary regarding the origins of secondary
considerations.
61
U.S. v. Adams, 383 U.S. 39, 51-52 (1966); KSR Int’l Co. v. Teleflex Inc., 550 U.S. at 416.
62
Honorable Giles Rich commented that he did “not believe the Supreme Court intended to signify
anything by the term ‘secondary’. . . . [and that secondary considerations should] be looked upon for what
they factually are, circumstantial evidence of unobviousness of the highest probative value[.]” Giles S.
Rich, Laying the Ghost of the “Invention” Requirement, in NONOBVIOUSNESS, supra note 52, at 1:513.
63
Merges, supra note 48, at 816.
64
Ruiz v. A.B. Chance Co., 234 F.3d 654, 668 (Fed. Cir. 2000) (citing Simmons Fastener Corp. v. Ill. Tool
Works, Inc., 739 F.2d 1573, 1575 (Fed. Cir. 1984)).
65
Ortho-McNeil Pharm., Inc. v. Mylan Labs., Inc., 348 F. Supp. 2d 713, 749 (N.D.W. Va. 2004), aff’d 161
Fed. Appx. 944 (Fed. Cir. 2005)).
66
Stratoflex, Inc. v. Aeroquip Corp., 713 F.2d 1530, 1538 (Fed. Cir. 1983).
67
Hybritech Inc. v. Monoclonal Antibodies, Inc., 802 F.2d 1367, 1380 (Fed. Cir. 1986).
68
Merck Sharp & Dohme Pharm., SRL v. Teva Pharm. USA, Inc., 2009 WL 3153316, at *50 (quoting
Hybritech Inc., 802 F.2d at 1380).
69
Zenith Goldline Pharmaceuticals is now known as Ivax Pharmaceuticals, Inc. See Eli Lilly & Co. v.
Zenith Goldline Pharm., Inc., 471 F.3d 1369, 1373 (Fed. Cir. 2006).
70
Eli Lilly & Co. v. Zenith Goldline Pharm., Inc., 364 F. Supp. 2d 820, 905-06 (S.D. Ind. 2005), aff’d, 471
F.3d 1369 (Fed. Cir. 2006).
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success; (4) the drug’s industry acclaim; and (5) the compound’s unexpected results, did
the court conclude olanzapine was unobvious.71
II. REBUTTING THE OBVIOUSNESS OF ANALOGS
A. Introduction to Drug Discovery and Analogs
Most drugs are classified as structurally specific, meaning that they act at specific
sites like a receptor or enzyme.72 So, the activity and potency of structurally specific
drugs are “very susceptible to small changes in chemical structure.” 73 During drug
discovery, chemists will modify a lead compound to generate structurally related
compounds, called analogs.74 This iterative process allows researchers to determine how
a compound’s biological activity is affected by structural modifications.75 After enough
analogs are prepared and studied, researchers can make conclusions regarding structureactivity relationships.76 Chemists will continue to make changes to a lead compound’s
structure until its pharmakinetic properties77 are optimized and its toxicity is minimized.78
To illustrate the role of analogs in drug development, consider the compounds in
Figure 1. Modifying the structure of lead compound A (called sulfanilamide when R = H)
resulted in analogs possessing diuretic, antidiabetic, and antimicrobial properties.79 In
order to understand the relationship between the compound’s structure and its biological
effects, over 10,000 compounds resembling compound A were synthesized and subjected
to biological testing.80 The results demonstrated that the skeletal framework present in all
compounds (shown in blue) was responsible, in part, for the observed biological
activity.81 However, analogs with different functional groups at the 4 position often
resulted in decreased potency.82 Thus, structure-activity-relationship studies, such as the
development of compounds B-D, allow scientists to modify the lead compound’s
structure to optimize its pharmakinetic properties.83

71

Id. at 906-09.
SILVERMAN, supra note 27, at 21-22.
73
Id. at 21.
74
Expert Report of John G. Gleason, Ph.D. on Patent Validity at 4, Merck Sharp & Dohme Pharm., SRL v.
Teva Pharm. USA, Inc., No. 07-1596 (GEB)(JJH), 2009 WL 3153316 (D.N.J. Aug. 19, 2009); for a
definition of analog see TRUDY MCKEE & JAMES R. MCKEE, BIOCHEMISTRY: AN INTRODUCTION 388 (Kent
A. Peterson et al. eds., 2d ed. 1999).
75
SILVERMAN, supra note 27, at 21-22.
76
Id. at 22.
77
Pharmacokinetic properties refer to a compound’s absorption, distribution, and metabolism in the body,
see Gleason, supra note 74, at 4.
78
Id.
79
SILVERMAN, supra note 27, at 10, 22.
80
Id. at 22.
81
Id.
82
Id.
83
Id.; see also Gleason, supra note 74, at 4.
72
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Figure 1: Analogs of sulfanilamide
B The Failure of Others and Long-felt but Unmet Needs
Advancing science is hard work. Even serendipitous discoveries are grounded in
the daily grind of research. As discussed earlier, Thomas Edison was not immediately
successful in his efforts towards a durable incandescent lamp conductor.84 Only after
extensive experimentation with nearly forty types of bamboo, which he acquired after
dispatching a messenger to China and Japan, did Edison bring the domestic lamp into
existence.85 In so doing, Edison was the first of “a large number of persons, in various
countries” to realize this goal.86 Stated differently, Edison’s success amidst the failure of
others highlighted the technical merit of his invention.
Just as a chemist will attach different functional groups to a lead compound,
Edison substituted bamboo for other conductors in an existing lamp design. Though the
argument could be made that Edison’s development was obvious, it ended in a product
that met society’s desire for artificial light.87 To this end, an invention that improves the
quality of life by satisfying a societal need should be rewarded. Although “long-felt need
does not prove that the race actually occurred or that the patentee won it,”88 it does set the
parameters of competition by defining a goal. Furthermore, as shown in Eli Lilly & Co. v.
Sicor Pharmaceuticals, Inc.89 and Merck Sharp & Dohme Pharmaceuticals, SRL v. Teva
Pharmaceuticals USA, Inc.,90 patent law rewards inventors who enrich the public domain
by achieving such goals, even in the face of allegations of obviousness.
i. Eli Lilly & Co. v. Sicor Pharmaceuticals, Inc.
1. Background of Nucleoside Analogs and Gemcitabine
84

The Incandescent Lamp Patent, 159 U.S. 465, 473-74 (1895).
Id. at 474.
86
Id. at 471.
87
See Tom Arnold, Future Considerations—Views of a Private Practitioner, in NONOBVIOUSNESS, supra
note 52, at 8:5 (commenting that “many of our most worthwhile inventions, including Edison’s electric
light patent . . . . would have been obvious to all [based upon prior art]”).
88
Merges, supra note 48, at 872.
89
Eli Lilly & Co. v. Sicor Pharm., Inc., 705 F. Supp. 2d 971 (S.D. Ind. 2010).
90
Merck Sharp & Dohme Pharm., SRL v. Teva Pharm. USA, Inc., 2009 WL 3153316 (D.N.J., Aug. 19,
2009).
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The case of Eli Lilly & Co. v. Sicor Pharmaceuticals, Inc. 91 concerns the
patentability of gemcitabine, which is sold for the treatment of ovarian, breast, lung, and
pancreatic cancer by Eli Lilly under the trade name Gemzar® (Figure 2).92 Nucleoside
analogs, like gemcitabine, are structurally related to naturally occurring nucleosides,
which are the building blocks of DNA.93 As shown in Figure 2, nucleosides consist of a
five-carbon sugar ring attached to a base.94 To avoid confusion when identifying atoms in
the base and sugar components, a superscript prime is used to label the atoms of the sugar
ring.95
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Figure 2: The naturally occurring nucleoside 2’-deoxycytidine and
nucleoside analog gemcitabine
“The chemical modification of nucleosides . . . [is] a major research topic in
bioorganic and medicinal chemistry.”96 Investigations into this class of compounds have
resulted in “life-saving drugs” that treat cancer and infectious diseases. 97 Modified
nucleosides can function as “anticancer or antiviral agents because they are similar
enough in structure to naturally occurring nucleosides that cells are tricked into accepting
them, but are different enough to disrupt cell functioning and replication once inside the
cell.”98
Because of the potential application of modified nucleosides to disease treatment,
chemists have been looking for biologically active nucleoside analogs “at least since the
1960s.”99 However, from the 1960s to the 1980s the synthesis of biologically active
nucleoside analogs “was largely a matter of serendipity.”100 Moreover, during the early
1980s, “fluorine chemistry as applied to the nucleoside field was relatively new, and little
91

Eli Lilly & Co. v. Sicor Pharm., Inc., 705 F. Supp. 2d 971.
Id. at 975.
93
Id. at 979.
94
Id.
95
TRUDY MCKEE & JAMES R. MCKEE, supra note 74, at 393-94.
96
Piet Herdewijn, Preface of MODIFIED NUCLEOSIDES: IN BIOCHEMISTRY, BIOTECHNOLOGY AND
MEDICINE, at XIX (Piet Herdewijn ed. 2008).
97
Id.
98
Eli Lilly & Co., 705 F. Supp. 2d at 979.
99
Id.
100
Piet Herdewijn, supra note 96, at XIX.
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was known about how one might synthesize difluorinated nucleosides.” 101 The key
difficulty in synthesizing gemcitabine was incorporating the two fluorine atoms at the C2’ position of the sugar group (see Figure 2).102 Even years after Eli Lilly produced
gemcitabine, one medicinal chemist wrote, “the synthesis of fluorinated nucleosides is
still a difficult task.”103
2. The Race for Gemcitabine
Researchers at the Sloan-Kettering Cancer Center began investigating the
biological activity of fluorinated nucleosides in the 1960s.104 These efforts resulted in
fluorinated nucleoside analogs 2’-F-ara-C105 and 2’-F-cytidine,106 which possess a single
fluorine atom attached to the 2’ carbon on the sugar ring (Figure 3). While these
compounds exhibited promising anticancer activity,107 they were not fully examined for
their medical utility until the late 1970s and early 1980s.108

HO
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Figure 3: Structures of 2’-F-ara-C and 2’-F-cytidine
In the 1980s, the application of fluorine chemistry to nucleosides still remained
largely unexplored.109 In particular, little was known about how to synthesize nucleosides
possessing two fluorine atoms attached to the same carbon (a geminal fluorine group).110
Dr. Mirslav Bobek, a medicinal chemist at Roswell Park Memorial Institute in Buffalo,
New York, spent most of his career developing methods to access therapeutic nucleoside
analogs.111 As shown in Figure 4, Dr. Bobek was successful at attaching two fluorine
atoms to the carbon atom outside of the sugar (called a gem-difluorosaccharide).112
However, he was unable to extend this methodology to the synthesis of gemcitabine and
101

Eli Lilly & Co., 705 F. Supp. 2d at 980.
Id.
103
Id.
104
Id. at 981.
105
A. Kyoichi et al., Nucleosides. 110. Synthesis and Antiherpes Virus Activity of Some 2’-Fluoro-2’deoxyarabinofuranosylpyrimidine Nucleosides, 22 J. MED. CHEM. 21, 21-22, (1979).
106
Iris L. Doerr & Jack J. Fox, Nucleosides. XXXIX. 2’-Deoxy-2’-fluorocytidine, 1-ß-D-ArabinofuranosyI2-amino-l,4(2H)-4-iminopyrimidine, and Related Derivatives, 32 J. ORG. CHEM. 1462, 1462-68 (1967).
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Eli Lilly & Co., 705 F. Supp. 2d at 1002.
108
Id. at 981.
109
Id. at 980.
110
Id.; see also R. A. Sharma et al., Synthesis of Gem- Difluorosaccharides, 95 TETRAHEDRON LETT. 3433,
3433 (1977).
111
Eli Lilly & Co., 705 F. Supp. 2d at 982.
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R. A. Sharma et al., supra note 110, at 3434-35.
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eventually abandoned his efforts towards the blockbuster drug. 113 Dr. Donald
Bergstrom114 also aimed his synthetic efforts towards gemcitabine.115 While he was able
to synthesize a 3’,3’-gemdifluoronucleoside (shown in Figure 5),116 like Dr. Bobek, he
never prepared gemcitabine and also abandoned his attempts for other nucleoside
analogs.117
O
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N
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Figure 4: Bobek’s
gem-difluorosaccharide

Figure 5: Bergstrom’s
3’,3-gemdifluoronucleoside

Like the many researchers probing the bounds of fluorine chemistry as applied to
therapeutic nucleosides, Eli Lilly pursued fluorinated nucleosides and tried to license
fluorinated compounds from Sloan Kettering.118 When the parties could not reach a
licensing agreement, Dr. Hertel, an Eli Lilly employee, proposed a new strategy to access
geminal difluoronucleosides. 119 Dr. Hertel believed his methods would produce a
nucleoside analog with two fluorine atoms at the C-2’ position, even though his proposal
was “dismissed by other researchers as a ‘method of limited usefulness.’”120
The key step in Dr. Hertel’s first proposed route to gemcitabine involved a
Sharpless epoxidation reaction.121 From May to September in 1981, Dr. Hertel attempted
to synthesize a compound that would lead to gemcitabine by “[trying] at least four
113

For select publications regarding modified nucleosides from Dr. Bobek’s laboratory, see J. Perman et.
al, Synthesis of 1-(2-deoxy-β-D-erythro-pentofuranosyl)-5-ethynyl-1,2,3,4-tetrahydropyrimidine-2,4-dione
(5-ethynyl-2'-deoxyuridine), 28 TETRAHEDRON LETT. 2427 (1976); Ram A. Sharma & Miroslav Bobek,
Acetylenic nucleosides. 1. Synthesis of 1-(5,6-Dideoxy-ß-D-ribo-hex-5-ynofuranosyl)uracil and 1-(2,5,6Trideoxy- ß-D-erythro-hex-5-ynofuranosyl)-5-methyluracil, 43 J. ORG. CHEM. 367 (1978); Miroslav Bobek
& Vicki Martin, The synthesis of anomeric 3-O-acetyl-5-O-benzoyl-2-azido-2-deoxy-D-arabinofuranosyl
chlorides. Versatile sugar intermediates for the synthesis of 2'-azido-2'-deoxy- and 2'-amino-2'-deoxy-β-Darabinofuranosyl nucleosides, 22 TETRAHEDRON LETT. 1919 (1978).
114
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115
Id.
116
Donald E. Bergstrom et al., 3’,3’-Difluoro-3’-deoxythymidine: Comparison of Anti-HIV Activity to 3’Fluoro-3’-deoxythymidine, 35 J. MED. CHEM. 3369, 3369-72 (1992).
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Eli Lilly & Co. v. Sicor Pharm., Inc., 705 F. Supp. 2d 971, 983 (S.D. Ind. 2010).
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Id. at 984.
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Id.
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Id.
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Id.; for the Sharpless epoxidation reaction mechanism, see JI JACK LI, NAME REACTIONS: A COLLECTION
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ed.
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categories” of the epoxidation reaction.122 When his efforts failed, Dr. Hertel consulted
with renowned Drs. Barry Sharpless123 and David Evans124 who both thought Hertel’s
route would prove successful.125 However, after months of failure, Hertel pursued a
second, more direct route that used DAST as a fluorine source.126 But this approach failed
too. Hertel then investigated a new route using a Reformatsky reaction,127 which finally
produced the desired difluoronated intermediate needed to access gemcitabine (Figure
6).128
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Figure 6: Hertel’s advanced intermediate en route to gemcitabine
Despite Hertel’s triumph in producing the difluorinated sugar, completing the
final steps of the gemcitabine synthesis was not a simple matter. “Introduc[ing] fluorine
into an organic molecule . . . significantly alters the chemistry of that molecule by
deactivating some centers or activating others to reactions . . . so essentially, you had to
kind of learn organic chemistry all over again.”129 As a result, Hertel spent the next nine
months trying to convert his intermediate into gemcitabine.130 Finally, in June 1982,
Hertel completed the first total synthesis of gemcitabine131 and its antiviral activity was
demonstrated later that month.132 Lilly filed its initial patent application for Hertel’s
fluorinated nucleoside on March 10, 1983.133 Subsequent testing revealed gemcitabine’s
“unprecedented activity against a broad spectrum of cancers.”134
3. The Aftermath of Gemcitabine’s Successful Conclusion
122

Eli Lilly & Co., 705 F. Supp. 2d at 984.
Nobel Prize-winning chemist who developed the Sharpless epoxidation reaction. See
http://www.scripps.edu/sharpless/ (last visted Jan. 6 2012).
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Professor of Chemistry at Harvard University. See http://www2.lsdiv.harvard.edu/labs/evans/index.html
(last visited Jan. 6 2012).
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Eli Lilly & Co., 705 F. Supp. 2d at 984-85.
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Id. at 985.
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Eli Lilly & Co., 705 F. Supp. 2d at 985; L. W. Hertel et al., Synthesis of 2-Deoxy-2,2-difluoro-D-ribose
and 2-Deoxy-2,2-difluoro-D-ribofuranosl Nucleosides, 53 J. ORG. CHEM. 2406 (1988).
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In 2010, generic pharmaceutical companies Sicor Pharmaceuticals, Inc. and Teva
Pharmaceuticals tried to invalidate Lilly’s patent on gemcitabine. 135 Of the many
arguments set forth, the generic drug companies argued that Lilly’s gemcitabine patent
was obvious based on its structural similarity to prior art.136 In particular, the defendants
contended that anticancer agents Ara-C, 2’-F-cytidine, and 2’-F-ara-C, and (Figure 7)
would have motivated a person of ordinary skill to synthesize Eli Lilly’s blockbuster
drug.137 But the Southern District of Indiana was not persuaded. In upholding Lilly’s
gemcitabine patent, the court emphasized the (1) “track record of failure prior to Lilly’s
success with gemcitabine,”138 and (2) long-felt need for treating pancreatic cancer,139
“one of the most lethal cancers.” 140
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Figure 7: Ara-C, 2-F-Ara-C, 2’-F-cytidine, and gemcitabine
The defendant pharmaceutical companies attempted to “prove obviousness by
virtue of gemcitabine’s structural similarity” to Ara-C, 2’-F-cytidine, and 2’-F-ara-C (see
Figure 7).141 This argument did not convince the court. Though the structural similarities
among these compounds may have been evident, the years spent formulating gemcitabine
show that its realization was not a foregone conclusion. A given compound may be an
obvious starting point for producing its structurally related analog, but it does not
necessarily provide “meaningful precedent”142 for the synthesis of its analogs. Visual
similarity does not always translate into a straightforward route in the laboratory.
Gemcitabine illustrates this point. Collectively, Drs. Bobek, Bergstrom, and researchers
at Merrell Dow 143 spent many years investigating numerous synthetic routes to
135

United States Patent No. 4,808,614. Eli Lilly & Co., 705 F. Supp. 2d at 975.
Id. at 1001-04.
137
Id. at 1001.
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Id. at 1009.
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gemcitabine.144 Yet, their “ultimately unsuccessful” attempts did not yield the compound
or any nucleoside analog with two fluorine atoms at the C-2’ position.145 Thus, the court
held that, “[i]n light of the fact that all of these methods were attempted and
unsuccessfully so in the years leading up to and including the time that Lilly invented
gemcitabine, it is abundantly clear that a person of ordinary skill in the art would have
been uncertain as to how to synthesize gemcitabine.”146
The need for a particular compound was also important to the obviousness
analysis in Eli Lilly. Before the development of gemcitabine, only two drugs, fluorouracil
(5-FU) and mitomycin, obtained FDA approval for the treatment of pancreatic cancer.147
And only 5-FU had been approved for treating solid tumors at the time the gemcitabine
patent application was filed.148 While “5-FU in particular held some promise for survival
benefit [for patients with pancreatic cancer],” it failed to “demonstrate a significant
increase in survival or pain relief.”149 Moreover, the anticancer agents that defendant
pharmaceutical companies proffered as prior art for gemcitabine were similarly
ineffective. “Ara-C was ‘good as an anticancer drug,’ [but] its usefulness was limited to
leukemia.” 150 Likewise, 2’-F-cytidine, and 2’-F-ara-C had insufficient antitumor and
antiviral activity and were abandoned by Sloan-Kettering “[b]ecause of such
deficiencies.”151
Unlike its predecessors, gemcitabine offers an improved one-year survival that is
nine times better than the previous treatment for pancreatic cancer.152 Since its FDA
approval in 1996, gemcitabine has been used universally to treat around 1.5 million
patients.153 While gemcitabine has a “broad efficacy in humans against a variety of
cancers,”154 it remains the leading treatment advanced pancreatic cancer.155 The court
noted that the National Comprehensive Cancer Network made gemcitabine—not 5-FU—
the “standard of care” for pancreatic cancer 156 and that gemcitabine exhibits an
“improved capacity to kill cancer cells over Ara-C.” 157 Furthermore, even though
pancreatic cancer continues to have “the worst mortality rate and the lowest overall
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survival (OS) in all cancers,”158 and gemcitabine is not a cure, “it was the first drug in
thirty years to produce an improvement in overall survival.”159
Given these facts, gemcitabine clearly filled a gap in cancer treatment. In
discussing the long-felt need, the district court stated, “despite the existence . . . [of
anticancer treatments before gemcitabine], the need for more effective chemotherapeutic
agents for the treatment of solid tumors like those in pancreatic cancer still existed in the
early 1980s.”160 As a result, patients with this disease “consistently faced a particularly
negative prognosis because no chemotherapy was available that was effective as a
treatment.”161 Thus, the district court held that “it is clear that gemcitabine met a long-felt
need.” The court’s consideration of the long-felt need for effective cancer treatment
speaks to the potentially large role that societal need can serve in the obviousness
analysis. It follows that pharmaceutical patentees who develop a drug that fills a gap in
medical treatment should survive an obviousness challenge—especially when coupled
with the failure of others to mend that gap.
ii. Merck Sharp & Dohme Pharmaceuticals, SRL v. Teva Pharmaceuticals USA, Inc. 162
Similarly, Merck Sharp & Dohme Pharmaceuticals, SRL v. Teva Pharmaceuticals
USA, Inc. illustrates the influential role of (1) others’ failure to bring an innovative drug
to market; and (2) the long-felt but unmet need for a safe and effective drug in evaluating
obviousness. The Merck case involved the development of Singulair®, an anti-asthma
medication realized after years of research into the field of leukotrienes.163,164 In an
attempt to invalidate Merck’s patent for montelukast, the active ingredient in Singulair®,
Teva argued that the creation of montelukast was obvious in view of the prior art.165 In
upholding Merck’s montelukast patent, the District Court for the District New Jersey
reviewed the history of leukotriene research, considered the need created by the asthma
epidemic, and ultimately disagreed with Teva’s obviousness argument.166
1. Background of Leukotrienes Chemistry and Biology
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“The leukotrienes story begins in the 1930s and 1940s” 167 when two
physiologists discovered that the guinea pig lung produces a substance that causes the
smooth muscle tissue in the lungs to contract.168 This substance was later called slowreacting substance of anaphylaxis, or SRS-A.169 Scientists hypothesized that SRS-A was
also produced in humans and “play[ed] a critical role in human asthma.”170
Even though research was initially impeded by SRS-A’s limited availability,
instability, and unknown structure, SRS-A nevertheless interested many researchers
studying asthma.171 For example, in 1973, scientists at Fisons Ltd. in England discovered
FPL-55712, a compound that prevented SRS-A from causing contractions in the smooth
muscle tissue, presumably by blocking SRS-A (see Figure 8).172 However, despite this
breakthrough, FPL-55712 was not an ideal drug candidate “because it was inactive when
taken orally (the ideal mode of dosing any drug) and had a very short half-life in the
body[,] even when it was given intravenously.”173
In the late 1970s, E.J. Corey 174 and coworkers discovered that SRS-A was
composed of three leukotrienes: leukotriene C4 (LTC4); leukotriene D4 (LTD4); and
leukotriene E4 (LTE4).175 These compounds act on a single common receptor,176 with
LTD4 being the most potent compound 177 (see Figure 8 for structure of LTD4).
Considering that LTD4 is the primary component of SRS-A, researchers theorized that
asthmatic reactions would be prevented by developing a compound that would bind with
the LTD4 receptor, thus blocking LTD4 .178
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2. The Pursuit of a Safe and Effective Asthma Treatment
Armed with new structural and biological information about SRS-A and LTD4,
many pharmaceutical companies entered the global race for a safe and effective asthma
treatment.179 In the 1980s, medicinal chemists either: (1) modified the structure of LTD4
or FPL-55712; or (2) screened for compounds showing promising activity.180 Smith Kline
& French (“SK&F”), now GlaxoSmithKline, initially modified the structure of LTD4.181
After substantial modifications and biological testing, SK&F synthesized a group of
promising compounds. 182 SK&F 104353 (also called pobliukast, Figure 9), one of
SK&F’s most biologically useful compounds, advanced to clinical trials in humans.183
However, SK&F terminated testing after pobliukast failed to show the required
efficacy.184 Scientists at SK&F subsequently reduced their work on in-house compounds
after licensing another LTD4 antagonist, pranlukast, from the Japanese company, Ono
Pharmaceuticals (shown in Figure 11).185
CO2H

S

CO2H
OH

Figure 9: SK&F 104353 (pobilukast)
Eli Lilly explored a different route towards an LTD4 antagonist by modifying the
structure of FPL-55712. 186 Lilly developed a number of compounds with promising
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biological activity,187 but Lilly later abandoned the drug candidates after studies revealed
liver toxicity in rats and mice.188
Imperial Chemical Industries (“ICI”) focused on the structural similarities
between both FPL-55712 and LTD4 itself (see Figure 8 for the structures of FPL-55712
and LTD4).189 After substantial research and development, ICI synthesized zarfirlukast,
which is sold under the brand name Accloate® by AstraZeneca (Figure 10).190 While
zarfirlukast has many positive qualities, it requires twice-a-day dosing191 and has caused
patients to suffer liver injury.192
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Figure 10: ICI 204219 (Accolate®)
Researchers at Ono Pharmaceuticals chose an alternative route by beginning their
studies with the lead compound shown in Figure 11, which was probably selected through
randomized screening.193 In collaboration with SK&F, Ono developed pranlukast (ONO
1078).194 SK&F subsequently abandoned their efforts towards pranlukast, while Ono
pursued the compound and currently sells the drug in Japan (Figure 11).195
O

O
N
H

CO2H

N
H
O

O
O
NH
N
N N

Ono's lead compound

pranlukast (ONO 1078)

Figure 11: Ono’s lead compound and pranlukast
Like Ono, researchers at Revlon Inc., Phone-Poulenc Rorer Pharmaceuticals Inc.,
and Wyeth Pharmaceuticals also chose a lead compound other than LTD4 and FPL-55712
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in the hopes of developing a better asthma treatment. 196 However, all companies
abandoned their respective compounds due to safety and efficacy concerns.197
In 1979, Merck began their search for an asthma treatment by screening their
chemical library for potential LTD4 antagonists.198 This resulted in a lead compound
whose structure was similar to FPL-55712.199 After substantial modifications and testing,
Merck developed L-649,923 and L-648,051 (Figure 12).200 These promising compounds
exhibited excellent LTD4 antagonist activity, but were ultimately abandoned due to
insufficient efficacy.201
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Figure 12: L-649,923 and L-648,051
“The Merck research team returned to the drawing board, identifying another lead
compound by screening Merck’s chemical library.”202 Merck chemists then modified a
different lead structure to yield L-660,711, also known as MK-0571 (Scheme 1).203 While
L-660,711 showed promising activity in humans, safety studies revealed that the
compound caused liver weight changes in animals, which could result in cancer.204 Upon
further analysis, Merck chemists found that only one of the enantiomers in L-660,711
caused the liver toxicity.205 Thus, the other enantiomer, called verlukast, progressed to
human clinic trials.206 Verlukast, however, raised new liver toxicity concerns and was
abandoned.207
196

Id. at 12-13.
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Despite earlier failures, Merck’s chemists did not abandon their efforts towards a
safe and effective LTD4 antagonist. Because of its promising activity, chemists used L660,711 as a foundation for further development.208 Then, “[u]sing a trial and error
approach,” chemists made many structural modifications to L-660,711 (Scheme 1).209 For
example, replacing the sulfur atom in the Q2 side chain with a carbon atom did not
change the compound’s potency. 210 Further studies showed that the amide group
prevented the compound from remaining in the body for the desired timeframe.211 To
overcome this obstacle, chemists replaced the amide with a variety of other groups, and
eventually found that incorporating a tertiary alcohol into the compound solved the short
half-life problem. 212 But further modification was still needed to overcome the
compound’s toxicity problems.213 The key was installing an additional carbon atom in the
Q1 side chain and attaching a cyclopropyl group at the beta-position.214 These final
changes resulted in montelukast215—a molecule that changed the world.216
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Scheme 1: Formation of montelukast from L-660,711
3. Winning the Race: the Success of Montelukast
In an attempt to invalidate Merck’s patent for montelukast, Teva argued that the
montelukast patent was obvious in view of prior art.217 Teva asserted that a person of
ordinary skill in the art would have selected its lead compound (Scheme 2) as a starting
point and converted it into montelukast through “at least eleven distinct steps.”218
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Teva’s proposed synthesis of montelukast begins by converting L-660,711 into
Teva’s lead compound (Scheme 2).219 According to Teva’s expert, Dr. George Lenz, it
would have been obvious to modify the Q2 side chain in L-660,711 by replacing the
sulfur atom with a carbon atom, adding a phenyl group, and then attaching a substituent
X to the phenyl ring.220 Choosing a dimethyl amide for the “X” position in Teva’s lead
structure would yield compound 97,221 a compound previously synthesized by Merck.222
Continuing from this point, one must then decide to modify compound 97 by replacing
the dimethyl amide with a tertiary alcohol, lengthening the Q1 side chain, adding a
cyclopropyl group to the beta position, and then resolving the enantiomers to yield the
desired enantiomer of montelukast.223
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Scheme 2: Teva’s proposed synthesis of Montelukast from L-660,711
via Teva’s lead compound
Teva’s lengthy projected pathway from L-660,711 to montelukast did not
convince the court that the road to montelukast was obvious. The structural similarity
between Teva’s lead compound and montelukast gives no indication of the immense
effort required to bridge the gap between the two. For example, the installation of the
219
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tertiary alcohol and the cyclopropyl group was no small feat. Replacing the dimethyl
amide in L-660,711 with the tertiary alcohol in montelukast was initially met with
skepticism.224 Dr. Robert Young, the leader of the Merck leukotriene team, reasoned that
even though tertiary alcohols and dimethyl amides are similar in size, the two moieties
have different shapes “in the area where you would expect hydrogen binding to occur”
and this dissimilarity in size “is [an] important difference.”225 Moreover, tertiary alcohols
like the one in montelukast (called a benzylic tertiary alcohol) are characteristically
unstable and “are expected to decompose in even mildly acidic conditions. So it is very
unusual to see a tertiary alcohol on a drug [due to the human stomach’s acidity].”226
Likewise, “cyclopropyl groups were difficult to make and therefore were not commonly
used [in drug development].”227 Furthermore, Dr. John Gleason, the leader of SK&F’s
leukotriene program testified “that ‘in this timeframe, 1990, cyclopropyl groups were not
easy to make’ and that ‘[c]yclopropyl is not commonly used.’”228
Further damaging to Teva’s obviousness argument is that medicinal chemists
from leading pharmaceutical companies used a variety of approaches to identify a lead
compound.229 Some researchers chose to modify the structure of the naturally occurring
compound LTD4, while others modified FPL-55712, and yet others fished for a lead
compound from a chemical library.230 This grab bag of approaches resulted in many
promising compounds that never made it to market. 231 Dr. Gleason of SK&F later
remarked that “over the period of about 12 years [SK&F] progressed several compounds
into human clinical trials, but was unsuccessful in progressing a single leukotriene
antagonist compound through to the market.”232 Likewise, “Eli Lilly & Co., Revlon,
Rhone-Poulenc Rorer, [and] Wyeth Pharmaceuticals” all had compounds in “advanced
stages of development” that were abandoned before commercial development. 233 Of
Merck’s many competitors, only Imperial Chemical Industries delivered a drug to the
marketplace, although Accolate® has liver toxicity side effects.234 Unlike its competitors,
Merck was successful in bringing a safe and effective asthma treatment to market. Thus,
the court could not ignore Merck’s triumph amidst “the failure of others to develop a
commercially useful leukotriene antagonist.”235 The court’s decision in Merck’s favor
further strengthens the causal link between the failure of others and a ruling of nonobviousness. In 1998, the FDA approved the use of Singulair® tablets236 to treat asthma
in pediatric and adult patients and other dosages to treat allergic conditions such as
224
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allergic rhinitis.237 Asthma is a chronic disease, which causes inflammation of the lung
airways. “The World Health Organization (WHO) estimated that 100-150 million people
worldwide (equivalent to about half the population of the USA) were suffering from
asthma in 2000, with the global death toll exceeding 180,000 per year.”238
While asthma treatments existed before the development of Singulair®, the
market had a long-felt need for a drug that had fewer side effects and was easier to
administer. Traditional treatments such as inhaling steroids were ineffective at low doses
and associated with “severe side effects at higher doses.”239 Moreover, long-acting beta
antagonists must be used in combination with an inhaled steroid and carry a “black box”
warning, which indicates side effects causing an increased chance of death.240 Further,
these “symptom-alleviating medication[s]” pale in comparison to Singulair®, which
“prevent[s] the [asthma] attack from occurring in the first place.”241 As a result, the
Merck court held that the “other drugs available prior to montelukast’s inception showed
significant shortcomings.”242
The district court also refused to let other leukotriene-related drugs like
Accolate® and Zyfo® stand in the way of Merck’s blockbuster. Simply put, Accolate®
and Zyfo® are not as safe and effective as Singulair®.243 Accolate®, another leukotriene
antagonist, must be taken twice a day, cannot be taken with food, and is plagued by liver
toxicity issues.244 Likewise, Zyflo®, a leukotriene inhibitor, must be taken four times a
day and is also associated with liver toxicity.245 On the other hand, Singulair® is “the
only LTD4 antagonist currently on the market that is indicated for once-a-day use.”246
Thus, the drug is easier to take than its competitors and is therefore advantageous for
treating children.247 Notably, the Global Initiative for Asthma (GINA) has recommended
“montelukast as an accepted management therapy for the treatment of asthma.”248 As a
result, the court concluded that “it is clear that montelukast fulfills a long-felt but
unsolved need for asthma and allergic rhinitis sufferers.”249 This decision rightly elevates
long-felt need to a position of importance in the obviousness analysis.
237
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III. APPLYING SECONDARY CONSIDERATIONS TO ANALOGS: CRITICAL RESPONSE AND
THE ROAD AHEAD
For several reasons, gemcitabine and montelukast are excellent case studies of the
practical considerations impacting the obviousness of structurally related compounds.
With an eye towards fulfilling a societal need in disease treatment, researchers in each
case modified the structure of a lead compound to yield a drug that immensely benefited
society. The methodical research process that produced gemcitabine and montelukast and
the years of failed attempts that preceded their development are typical of drug
discovery.250 As such, these cases show that practical considerations such as the failure of
others and long-felt need are especially relevant to the drug discovery process.
As is characteristic of courts considering the obviousness of structurally related
compounds, both district courts placed primary emphasis on the unexpected efficacy and
safety of gemcitabine and montelukast.251 However, the district courts found additional
support for non-obviousness in the failure of others and long-felt need. This fact is a
necessary step towards acknowledging the important role of these secondary
considerations in the obviousness analysis of structurally related compounds. However,
the courts’ opinions neglect to elevate these factors to a leading position in the analysis,
which would be consistent with their applicability to the drug development process.
Going forward, when considering the obviousness of structurally related
compounds like analogs, courts should place the utmost importance on the failure of
others to develop a drug and the long-felt but unmet need that the drug fulfills. Because
these factors are in step with the path of drug development, allowing pharmaceutical
patentees to rely on these practical factors when seeking patent rights will encourage
innovator firms to purse complex research and not abandon their efforts after
disappointing results. “Many times during the course of human history, small molecules
have cured tens of millions of people of serious diseases and improved the quality of
life.”252 Surely the patentability of structurally related molecules should not turn on
whether a researcher expresses surprise that one molecule is more effective as a treatment
250
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than its analog. Scientific research that sets out to meet a need and succeeds in achieving
it where others fail must be deemed equally, if not more, worthy of patent protection. By
promoting the latter goal, courts will encourage scientists to work on hard problems
whose resolutions can change lives for the better.
CONCLUSION
“Close involvement with society is the destiny of science.”253 Molecules that have
a profound impact on society, like gemcitabine and montelukast, fulfill society’s long-felt
need to cure disease and improve the quality of life. Scientific research would be stifled if
chemical patents could be invalidated merely because a compound resembles another
previously developed or because a compound’s properties aren’t unexpected. Using
pragmatic considerations such as the failure of others to produce a compound (itself a
“superior indicator” of patentability254) and that compound’s ability to meet a societal
need can prove a powerful argument against obviousness. These factors will encourage
inventors to continue along the path of discovery—even after years of wrong turns. Firms
that conclude the race by delivering a needed drug to market should be compensated.
Such were the cases of gemcitabine and montelukast.
In highlighting the underappreciated realities of the drug discovery process, the
immense effort that precedes a drug’s delivery to market, and the profound effect
pharmaceuticals can have on disease treatment, this Note argues for the elevation of the
failure of others and long-felt need in the obviousness analysis. Allowing researchers to
rely on factors synchronized with the nature of chemical research for patent protection,
rather than unpredictable results, will help drive pharmaceutical science. Because
innovator drug firms rely on patent protection to fuel expensive and time-consuming R &
D, the promise of a financial reward for developing a marketable drug is crucial to drug
development. By rewarding companies that deliver effective drugs for diseases that
plague society, patent laws have the power to encourage companies to persevere in the
face of long odds.
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